Wockhardt's Zaynich Fast-Tracked in Europe, Unlocking Massive Revenue Potential

• Wockhardt's antibiotic Zaynich received accelerated assessment from the European Medicines Agency (EMA).
• This fast-track shortens approval timelines, allowing quicker access to the 27-country European market.
• Habil Khorakiwala expects approval by July/August, targeting over 200,000 patients with drug-resistant infections.
• Europe alone could add $400-500 million to Zaynich's revenue potential, expanding global opportunity.
• Wockhardt aims to double revenues to ₹6,000 crore by FY28 and ₹12,000 crore by FY31.

Why It Matters: EU fast-track for Zaynich significantly boosts Wockhardt's revenue and global market access.